Highest-materiality recent filing
Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M
Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.
Emmaus appoints Henry H. Du to board; replaces resigned director Jon Kuwahara
Henry H. Du appointed to fill board vacancy created by resignation of Jon Kuwahara; expected to become sole Audit Committee member.
Director Jon Kuwahara resigns from Emmaus Life Sciences board
Director Jon Kuwahara resigned from the board of Emmaus Life Sciences on April 13, 2026, effective April 15, 2026.
Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M
Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).
Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada
Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.
Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties
Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.
Emmaus Life Sciences exchanges $3M note for $600K note and 6.33M shares (9% dilution)
Exchanged $3M convertible note (10% interest, conversion $0.13) for $600K new note (10%, conversion $0.01 adjustable) and 6,332,692 shares valued at ~$0.38 each.
Director Ian Zwicker resigns from Emmaus Life Sciences board, effective Dec. 31, 2025
Ian Zwicker resigned as director of Emmaus Life Sciences, effective December 31, 2025.
Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition
Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.
Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M
Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
Emmaus CFO Yasushi Nagasaki resigns effective June 30, 2025; Hiroko Huynh promoted to CAO
Yasushi Nagasaki resigned as CFO, effective June 30, 2025, transitioning to full retirement.
Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M
Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.
Emmaus Life Sciences replaces auditor Marcum with CBIZ CPAs after acquisition of attest business
Marcum resigned as independent auditor on May 2, 2025, due to CBIZ CPAs acquiring its attest business.
Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share
Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.
Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY
Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.
Director Seah Lim resigns from Emmaus Life Sciences board for personal reasons
Dr. Seah Lim resigned as director on November 4, 2024, citing personal reasons.
Emmaus Life Sciences engages Marcum LLP as new auditor for FY 2024
Audit Committee appointed Marcum LLP as independent accountant on October 22, 2024.
Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed
George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.
Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment
Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.
Emmaus Life Sciences appoints Willis Lee as CEO, eliminates interim Co-President role
Willis Lee appointed CEO effective July 15, 2024; previously interim Co-President and COO.
Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M
Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.
Emmaus Life Sciences amends bylaws to establish exclusive forum for stockholder litigation
Board adopted Amendment to Amended and Restated By-Laws on May 23, 2024.
On November 4, 2024, Seah Lim, M.D., Ph.D., resigned as a director of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) for personal reasons and expressed his best wishes to the company.
the Board appointed Jon Kuwahara to fill the resulting vacancy on the Board of Directors. The Board also appointed Mr. Kuwahara to serve as the Chair of the two-person Audit Committee.
On September 30, 2024, George Sekulich resigned as a member of the Board of Directors
in connection with the termination of his employment as our Chief Commercial Officer on October 4, 2024
On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.
Max materiality 0.80 · Median 0.53 · Most common event earnings